ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 254 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,760,898 | +2.3% | 735,426 | +35.8% | 0.00% | 0.0% |
| Q2 2023 | $19,313,955 | +19.9% | 541,614 | -14.6% | 0.00% | 0.0% |
| Q1 2023 | $16,110,409 | -7.9% | 634,268 | +47.1% | 0.00% | 0.0% |
| Q4 2022 | $17,488,944 | +23.8% | 431,187 | +0.9% | 0.00% | 0.0% |
| Q3 2022 | $14,126,000 | -25.6% | 427,393 | -20.7% | 0.00% | 0.0% |
| Q2 2022 | $18,976,000 | +35.7% | 538,971 | +77.3% | 0.00% | 0.0% |
| Q1 2022 | $13,983,000 | -35.7% | 304,040 | -7.3% | 0.00% | -33.3% |
| Q4 2021 | $21,737,000 | +22.9% | 327,865 | +15.7% | 0.00% | +50.0% |
| Q3 2021 | $17,691,000 | +12.9% | 283,366 | +49.7% | 0.00% | 0.0% |
| Q2 2021 | $15,675,000 | -37.3% | 189,280 | -49.8% | 0.00% | -50.0% |
| Q1 2021 | $25,012,000 | -39.2% | 377,209 | -29.7% | 0.00% | -33.3% |
| Q4 2020 | $41,164,000 | +86.0% | 536,479 | +4.4% | 0.01% | +50.0% |
| Q3 2020 | $22,129,000 | +263.5% | 513,883 | +264.6% | 0.00% | +300.0% |
| Q2 2020 | $6,087,000 | -49.6% | 140,961 | -66.4% | 0.00% | -66.7% |
| Q1 2020 | $12,083,000 | -54.7% | 419,953 | -0.1% | 0.00% | -50.0% |
| Q4 2019 | $26,661,000 | +46.0% | 420,328 | -35.1% | 0.01% | +20.0% |
| Q3 2019 | $18,264,000 | +33.5% | 648,127 | +25.6% | 0.01% | +25.0% |
| Q2 2019 | $13,676,000 | +179.3% | 516,057 | +93.4% | 0.00% | +300.0% |
| Q1 2019 | $4,896,000 | +88.2% | 266,817 | +27.4% | 0.00% | 0.0% |
| Q4 2018 | $2,601,000 | -40.1% | 209,399 | -7.5% | 0.00% | 0.0% |
| Q3 2018 | $4,339,000 | +13.0% | 226,406 | -19.8% | 0.00% | 0.0% |
| Q2 2018 | $3,839,000 | +192.2% | 282,371 | +55.1% | 0.00% | – |
| Q1 2018 | $1,314,000 | +15.8% | 182,113 | -41.0% | 0.00% | – |
| Q4 2017 | $1,135,000 | +331.6% | 308,467 | +407.7% | 0.00% | – |
| Q3 2017 | $263,000 | -30.1% | 60,762 | -73.7% | 0.00% | – |
| Q2 2017 | $376,000 | -53.6% | 231,332 | -47.1% | 0.00% | – |
| Q1 2017 | $810,000 | -42.3% | 436,998 | -51.7% | 0.00% | – |
| Q4 2016 | $1,404,000 | +33.2% | 905,652 | +531.0% | 0.00% | – |
| Q3 2016 | $1,054,000 | +201.1% | 143,526 | +118.3% | 0.00% | – |
| Q2 2016 | $350,000 | – | 65,751 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Western Financial Corp/CA | 820,320 | $33,272,179 | 21.56% |
| Aquilo Capital Management, LLC | 1,103,515 | $44,758,568 | 16.81% |
| M28 Capital Management LP | 143,900 | $5,836,584 | 5.56% |
| WEALTH EFFECTS LLC | 155,620 | $6,311,951 | 3.60% |
| Evolutionary Tree Capital Management, LLC | 92,095 | $3,735,373 | 3.59% |
| Privium Fund Management B.V. | 221,015 | $8,867,122 | 3.36% |
| JOHNSON & JOHNSON | 247,598 | $10,043 | 2.92% |
| COMMODORE CAPITAL LP | 462,111 | $18,743 | 2.82% |
| Avidity Partners Management LP | 1,375,000 | $55,770,000 | 1.21% |
| Capital Impact Advisors, LLC | 26,853 | $1,089,158 | 1.06% |